Relevant bibliographies by topics / SNP309

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers

Academic literature on the topic 'SNP309'

Author: Grafiati
Published: 4 June 2021
Last updated: 10 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'SNP309.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "SNP309"

1

Miedl, Heidi, Jürgen Lebhard, Lisa Ehart, and Martin Schreiber. "Association of the MDM2 SNP285 and SNP309 Genetic Variants with the Risk, Age at Onset and Prognosis of Breast Cancer in Central European Women: A Hospital-Based Case-Control Study." International Journal of Molecular Sciences 20, no. 3 (2019): 509. http://dx.doi.org/10.3390/ijms20030509.

Full text
Abstract:
SNP309T>G (rs2279744) and SNP285G>C (rs117039649) in the MDM2 promoter are thought to have opposite effects on the binding of transcription factor SP1 (specificity protein 1), and consequently on MDM2 expression, p53 levels, cancer risk, age at onset, and prognosis. Here, we genotyped SNP309 and SNP285 in 406 Austrian breast cancer patients and 254 female controls. The SNP309GG genotype was associated with an increased breast cancer risk in p53 negative (OR, 1.82; 95% CI, 1.09–3.03; p = 0.02), but not p53 positive or unselected patients. In contrast, the SNP309TT genotype was associated
APA, Harvard, Vancouver, ISO, and other styles
2

Mackay, H. J., P. Bradbury, K. Asomaning, et al. "Stage and histology influence the relationship between MDM2 promoter polymorphism and esophageal cancer and overall survival (OS)." Journal of Clinical Oncology 25, no. 18_suppl (2007): 21047. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.21047.

Full text
Abstract:
21047 Background: A single nucleotide polymorphism in the MDM2 promoter (SNP309) has been found to affect OS of advanced stage gastric adenocarcinoma (AD) and early stage squamous (SQ) cell carcinoma of the lung. The aim of this study was to evaluate the role of this polymorphism in the prognosis of esophageal cancer, another aerodigestive cancer. Methods: 150 early stage (E) and 118 locally advanced stage (LA) esophageal cancers were genotyped for MDM2 SNP309 using Taqman. The primary endpoint was overall survival (OS). Results: E disease: n=23 stage I; n=127 stage II. LA disease: n=93, Stage
APA, Harvard, Vancouver, ISO, and other styles
3

Gryshchenko, Irina, Sebastian Hofbauer, Markus Stoecher, et al. "MDM2 SNP309 Is Associated With Poor Outcome in B-Cell Chronic Lymphocytic Leukemia." Journal of Clinical Oncology 26, no. 14 (2008): 2252–57. http://dx.doi.org/10.1200/jco.2007.11.5212.

Full text
Abstract:
Purpose A single nucleotide polymorphism (SNP) at position 309 in the promoter region of MDM2 leading to increased expression of MDM2 and attenuated function of p53 has been negatively associated with onset and outcome of disease in solid tumors. Because inactivation of p53 by deletion and/or mutations also impacts on the clinical course of B-cell chronic lymphocytic leukemia (B-CLL), we assessed the role of the SNP309 genotype in B-CLL. Patients and Methods The frequency of SNP309 T/T, T/G, or G/G genotypes and the p53 status (wild type, mutated, or deleted) were assessed and correlated with
APA, Harvard, Vancouver, ISO, and other styles
4

Ohmiya, Naoki, Ayumu Taguchi, Nobuyuki Mabuchi, et al. "MDM2Promoter Polymorphism Is Associated With Both an Increased Susceptibility to Gastric Carcinoma and Poor Prognosis." Journal of Clinical Oncology 24, no. 27 (2006): 4434–40. http://dx.doi.org/10.1200/jco.2005.04.1459.

Full text
Abstract:
PurposeRecently, a single-nucleotide polymorphism in the MDM2 promoter (SNP309) has been found to lower the age of onset of tumors and increase the occurrence of multiple primary tumors in Li-Fraumeni syndrome, and accelerate the development of sporadic adult soft tissue sarcoma. The aim of this study was to determine whether SNP309 is associated with susceptibility to gastric carcinoma and its prognosis.Patients and MethodsIn a case-control study including 438 controls and 410 patients with sporadic gastric carcinoma, MDM2 SNP309 was genotyped. Serum pepsinogens (PGs) I and II were measured i
APA, Harvard, Vancouver, ISO, and other styles
5

Dong, Hua-Jie, Cheng Fang, Lei Fan, et al. "MDM2 Promoter SNP309 Is Associated with An Increased Susceptibility to Chronic Lymphocytic Leukemia and Correlates with MDM2 mRNA Expression In Chinese Population." Blood 116, no. 21 (2010): 2424. http://dx.doi.org/10.1182/blood.v116.21.2424.2424.

Full text
Abstract:
Abstract Abstract 2424 Objective: A single nucleotide polymorphism (SNP) at position 309 in the promoter region of MDM2 leading to increased expression of MDM2 and attenuated function of p53 has recently been suggested as an unfavorable prognostic marker in chronic lymphocytic leukemia (CLL) although this has been questioned. Because inactivation of p53 by deletion and/or mutations also impacts on the clinical course of CLL, we assessed the role of the SNP309 genotype in CLL among Chinese populations. Methods: The MDM2 SNP309 genotypes in 166 CLL patients and 260 healthy controls were detected
APA, Harvard, Vancouver, ISO, and other styles
6

Pine, S. R. "MDM2 SNP309 and SNP354 Are Not Associated with Lung Cancer Risk." Cancer Epidemiology Biomarkers & Prevention 15, no. 8 (2006): 1559–61. http://dx.doi.org/10.1158/1055-9965.epi-06-0217.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Nechushtan, H., T. Hamburger, S. Mendelson, et al. "Superior survival of breast cancer BRCA1 /2 mutation carriers harboringG/G at the -309 position at the MDM2 promoter compared to those harboring T/T or G/T at this SNP." Journal of Clinical Oncology 25, no. 18_suppl (2007): 10600. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.10600.

Full text
Abstract:
10600 Background: A germ line single polymorphism in the promoter of the gene encoding the important modulator of P53, MDM2 has been described. The findings of G/G nucleotides at this position in contrast to G/Tor T/T were demonstrated to increase MDM2 transcriptional levels and were correlated with younger onset of cancers in patients with the Li-Fraumeni syndrome. Furhtermore gastric cancer patients harboring T/T at this position and treated with chemotherapy were found to have decresed survival compared to the other SNP carriers. P53 mutations appear in high frequency in tumors associated w
APA, Harvard, Vancouver, ISO, and other styles
8

Lee, Hyunjoo, Anthony Liew, Annette Lee, et al. "Effect of Polymorphisms in p53 Pathway Proteins and B-Chronic Lymphocytic Leukemia Disease Progression,." Blood 118, no. 21 (2011): 3888. http://dx.doi.org/10.1182/blood.v118.21.3888.3888.

Full text
Abstract:
Abstract Abstract 3888 In B-CLL, mutations in the IGHV genes encoding the BCR are correlated with disease aggressiveness: patients with unmutated BCR (U-CLL) typically have a worse prognosis than those with mutated BCR (M-CLL). Evidence that many U-CLL express BCR with specificity toward apoptotic cell antigens suggests that dying cells provide pro-survival signals for U-CLL clones. Thus progression of U-CLL may depend both on mechanisms that ensure the clone's survival and those that promote cell death. A single nucleotide polymorphism (SNP) within the p53 gene at codon 72 significantly affec
APA, Harvard, Vancouver, ISO, and other styles
9

Vivenza, Daniela, Martino Monteverde, Laura Lattanzio, et al. "Correlation of TP53 and MDM2 Genotypes and Clinical Outcome in Platinum-Treated Head and Neck Cancer Patients with More than 10 Years’ Follow-Up." International Journal of Biological Markers 31, no. 2 (2016): 183–92. http://dx.doi.org/10.5301/jbm.5000192.

Full text
Abstract:
Purpose Adequate biomarkers are still required to optimize therapy in patients with locally advanced head and neck squamous carcinomas (HNSCC) treated with chemoradiotherapy (CRT). Methods We updated the follow-up of 66 HNSCC patients treated with CRT we described more than 10 years ago, focusing on SNP Arg/Pro (R/P) at codon 72 and somatic mutations in TP53 and on SNP309 in the MDM2 gene. Results In wild-type TP53 cases, overall survival (OS) was longer in 72RR and less favorable in 72PP (p = 0.005); when TP53 was mutated, OS was longest in 72PP and less favorable in 72RR and 72RP (p = 0.058)
APA, Harvard, Vancouver, ISO, and other styles
10

Sun, S., X. Xie, J. H. Schiller, J. D. Minna, and G. Tomlinson. "The functional MDM2 SNP309 polymorphism is associated with an earlier age of diagnosis in women with lung cancer." Journal of Clinical Oncology 25, no. 18_suppl (2007): 10550. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.10550.

Full text
Abstract:
10550 Background: MDM2 protein is a key negative regulator of p53 protein by targeting its destruction through the ubiquitin pathway. A single nucleotide polymorphism (SNP309 T→G) has been identified in the promoter of the MDM2 gene which results in higher levels of MDM2 protein, attenuation of the p53 pathway, and enhanced tumorigenesis. Estrogen signaling has also been shown to upregulate MDM2 expression. Recent studies have suggested that the MDM2 SNP309 polymorphism is associated with earlier age of onset of certain cancers, particularly in women. The purpose of this study was to determine
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "SNP309"

1

Entiauspe, Ludmila Gonçalves. "Infecção por HPV e polimorfismos nos genes TP53 e MDM2 em mulheres HIV positivas e negativas." Universidade Federal de Pelotas, 2013. http://guaiaca.ufpel.edu.br/handle/123456789/1210.

Full text
Abstract:
Made available in DSpace on 2014-08-20T13:32:46Z (GMT). No. of bitstreams: 1 Tese_Ludmila_Goncalves_Entiauspe.pdf: 1808464 bytes, checksum: 8834f78745c1e2d7f757d36d4797ef5c (MD5) Previous issue date: 2013-03-08<br>Estimates show that approximately 80% of sexually active women will be infected by the Human Papillomavirus (HPV) in some point of their life course, and HPV DNA has been found in 99,7% of cervical cancer (CC) cases. Thus, several factors may contribute to CC development, including co-infections with Human Immunodeficiency Virus (HIV), as well as genetic factors, including TP53 a
APA, Harvard, Vancouver, ISO, and other styles
2

Thurow, Helena Strelow. "Epidemiologia genômica: estudos de polimorfismos nos genes da p53 e MDM2 associados a fatores de risco para câncer." Universidade Federal de Pelotas, 2011. http://guaiaca.ufpel.edu.br/handle/123456789/1289.

Full text
Abstract:
Made available in DSpace on 2014-08-20T13:32:57Z (GMT). No. of bitstreams: 1 tese_helena_strelow_thurow.pdf: 807973 bytes, checksum: 9ce5f5a742c1cda1d087be4eaaf27eae (MD5) Previous issue date: 2011-07-15<br>A proteína p53,codificada pelo gene TP53, vem sendo estudada há mais de 30 anos e já foi denominada de "guardiã do genoma.
APA, Harvard, Vancouver, ISO, and other styles
3

Zainuddin, Norafiza. "Molecular Genetic Analysis in B-cell Lymphomas : A Focus on the p53 Pathway and p16INK4a." Doctoral thesis, Uppsala universitet, Institutionen för onkologi, radiologi och klinisk immunologi, 2010. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-113970.

Full text
Abstract:
The presence of TP53 mutations has been associated with inferior outcome in diffuse large B-cell lymphoma (DLBCL) and chronic lymphocytic leukemia (CLL). In DLBCL, the impact of the TP53 codon 72 polymorphism and MDM2 SNP309 has not been clearly elucidated, whereas MDM2 SNP309 was suggested as a poor-prognostic marker in CLL. In addition, p16INK4a promoter hypermethylation has been implicated as a negative prognostic factor in DLBCL. The aim of this thesis was to further evaluate these molecular markers in well-characterised materials of DLBCL and CLL. In paper I, we investigated the prognosti
APA, Harvard, Vancouver, ISO, and other styles
4

Wenners, Antonia Sophie [Verfasser]. "Die Rolle des MDM2-SNP309 beim sporadischen Nierenzellkarzinom / vorgelegt von Antonia Sophie Wenners." 2010. http://d-nb.info/1001483081/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

HsinHung and 洪昕. "Cancer Risk Assessment of Germline TP53, MDM2 SNP309 and Sex in a Family Study of Li-Fraumeni Syndrome." Thesis, 2018. http://ndltd.ncl.edu.tw/handle/tkay5f.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Müller, Monika Barbara [Verfasser]. "Zur Bedeutung des SNP309 des Mdm2-Gens für die CVID und die rheumatoide Arthritis / vorgelegt von Monika Barbara Müller." 2008. http://d-nb.info/996729593/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "SNP309"

1

Cattelani, Sara, Giovanna Ferrari-Amorotti, Angela Rachele Soliera, Gloria Manzotti, Giuseppe Raschellà, and Bruno Calabretta. "Neuroblastoma: Role of MDM2 and SNP309 as Markers." In Pediatric Cancer, Volume 4. Springer Netherlands, 2013. http://dx.doi.org/10.1007/978-94-007-6591-7_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Villars, P., K. Cenzual, J. Daams, et al. "SnP3." In Structure Types. Part 5: Space Groups (173) P63 - (166) R-3m. Springer Berlin Heidelberg, 2007. http://dx.doi.org/10.1007/978-3-540-46933-9_474.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "SNP309"

1

Brekman, A., K. Talbott, and J. Bargonetti. "p53 transcriptional activity is selectively suppressed by estrogen in SNP309 mdm2 overexpressing breast cancer cells." In CTRC-AACR San Antonio Breast Cancer Symposium: 2008 Abstracts. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-4065.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Rosso, Melissa, Alla Polotskaia, and Jill Bargonetti. "Abstract 468: Cancer cells with G/G mdm2 SNP309 have compromised transcriptional elongation of p53 target genes." In Proceedings: AACR Annual Meeting 2014; April 5-9, 2014; San Diego, CA. American Association for Cancer Research, 2014. http://dx.doi.org/10.1158/1538-7445.am2014-468.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Deschoolmeester, Vanessa, Christophe Deben, Marc Baay, et al. "Abstract 2103: High resolution melting analysis: a sensitive screening method for the detection of MDM2 promotor SNP309." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-2103.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Stoehr, Christine G., Robert Stoehr, Antonia Wenners, et al. "Abstract 3700: Association of the G/G-SNP309 variant in the mdm2 gene with earlier tumor onset in female renal cell carcinoma patients." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-3700.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'SNP309' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography